Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Roku Q3 Earnings Beat Estimates, Device Weakness Weighs on Stock
Roku Q3 Earnings Beat Estimates, Device Weakness Weighs on Stock

Roku ROKU reported third-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus Estimate of 7 cents. The company had incurred a loss of 6 cents per share in the year-ago

LendingTree Q3 Earnings Top Estimates, EBITDA Improves Y/Y
LendingTree Q3 Earnings Top Estimates, EBITDA Improves Y/Y

LendingTree, Inc.’s TREE third-quarter 2025 adjusted net income per share of $1.70 topped the Zacks Consensus Estimate of $1.23 per share. The figure compares favorably with the 80 cents reported in

SBUX Q4 Earnings Sees First Global Comp Growth in Seven Quarters
SBUX Q4 Earnings Sees First Global Comp Growth in Seven Quarters

Starbucks Corporation SBUX marked a key inflection point in its turnaround journey, reporting the first global comparable store sales growth in seven quarters in fiscal fourth-quarter 2025. The

ENVX Stock Before Q3 Earnings: Should You Buy Now or Wait for Results?
ENVX Stock Before Q3 Earnings: Should You Buy Now or Wait for Results?

Enovix Corporation ENVX is scheduled to report third-quarter 2025 results on Nov. 5.For the third quarter of 2025, Enovix expects total revenues to be between $7.5 million and $8.5 million

Live Nation Gears Up to Report Q3 Earnings: Factors to Note
Live Nation Gears Up to Report Q3 Earnings: Factors to Note

Live Nation Entertainment, Inc. LYV is scheduled to report third-quarter 2025 results on Nov. 4, after market close. In the last reported quarter, the company’s adjusted earnings per share (EPS)

SIMO Q3 Earnings Surpass Estimates on Healthy Revenue Growth
SIMO Q3 Earnings Surpass Estimates on Healthy Revenue Growth

Silicon Motion SIMO reported relatively healthy third-quarter 2025 results, with both the top and bottom lines beating the Zacks Consensus Estimate.The leading developer of microcontroller

YUM Gears Up for Q3 Earnings: What's in Store for the Stock?
YUM Gears Up for Q3 Earnings: What's in Store for the Stock?

YUM! Brands, Inc. YUM is scheduled to report third-quarter 2025 results on Nov. 4, before the opening bell. In the last reported quarter, the company’s bottom line missed the Zacks Consensus

Zillow Misses Q3 Earnings Estimates Despite Higher Revenues
Zillow Misses Q3 Earnings Estimates Despite Higher Revenues

Zillow Group ZG reported relatively mixed third-quarter 2025 results, wherein the bottom line missed the Zacks Consensus Estimate but the top line beat the same. The company registered a healthy

Aon Q3 Earnings Beat Estimates on Reinsurance Solutions Strength
Aon Q3 Earnings Beat Estimates on Reinsurance Solutions Strength

Aon plc AON reported third-quarter 2025 adjusted earnings of $3.05 per share, which beat the Zacks Consensus Estimate by 5.5%. The bottom line increased 12% from the year-ago period.

Total revenues

Cadence Q3 Earnings Top on Upbeat AI Trends, Backlog Remains Robust
Cadence Q3 Earnings Top on Upbeat AI Trends, Backlog Remains Robust

Cadence Design Systems CDNS, a well-known player in the electronic design automation (“EDA”) space, recently reported better-than-expected third-quarter 2025 results and exceeded management’s

Grainger Q3 Earnings & Revenues Surpass Estimates, Increase Y/Y
Grainger Q3 Earnings & Revenues Surpass Estimates, Increase Y/Y

W.W. Grainger, Inc. (GWW) has reported earnings per share (EPS) of $10.21 in third-quarter 2025, beating the Zacks Consensus Estimate of $9.93. The bottom line improved 3.4% year over year, aided by

Bandwidth Q3 Earnings Fall Short of Estimates, Revenues Decline
Bandwidth Q3 Earnings Fall Short of Estimates, Revenues Decline

Bandwidth Inc. BAND reported mixed third-quarter 2025 results, with the top line surpassing the Zacks Consensus Estimate but the bottom line missing the same.The company’s revenues declined

Federal Realty Beats Q3 FFO & Revenue Estimates, Raises 2025 View
Federal Realty Beats Q3 FFO & Revenue Estimates, Raises 2025 View

Federal Realty Investment Trust’s FRT third-quarter 2025 funds from operations (FFO) per share of $1.77 surpassed the Zacks Consensus Estimate of $1.76. This compares favorably with the FFO of $1.71

BITF vs. RZLV: Which High-Risk Tech Stock Should You Bet On?: https://staticx-tuner.zacks.com/images/articles/main/29/187.jpg
BITF vs. RZLV: Which High-Risk Tech Stock Should You Bet On?

Both Rezolve Ai RZLV and Bitfarms Ltd. BITFare speculative equity bets operating in emerging niches. RZLV has captured the AI-commerce and digital retail tech space, targeting to monetize enterprise

CAVA Stock Before Q3 Earnings: Is it Time to Buy or Sit Tight?
CAVA Stock Before Q3 Earnings: Is it Time to Buy or Sit Tight?

CAVA Group, Inc. CAVA is slated to release third-quarter 2025 results on Nov. 4, after the closing bell.

In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by

3 Reasons Why Grupo Cibest (CIB) Is a Great Growth Stock
3 Reasons Why Grupo Cibest (CIB) Is a Great Growth Stock

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock

Here is Why Growth Investors Should Buy HCI Group (HCI) Now
Here is Why Growth Investors Should Buy HCI Group (HCI) Now

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth

3 Reasons Why AppLovin (APP) Is a Great Growth Stock
3 Reasons Why AppLovin (APP) Is a Great Growth Stock

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to

3 Reasons Why Growth Investors Shouldn't Overlook Agnico (AEM)
3 Reasons Why Growth Investors Shouldn't Overlook Agnico (AEM)

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth

Amazon (AMZN) is an Incredible Growth Stock: 3 Reasons Why
Amazon (AMZN) is an Incredible Growth Stock: 3 Reasons Why

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to

Is Kaiser (KALU) a Solid Growth Stock? 3 Reasons to Think "Yes"
Is Kaiser (KALU) a Solid Growth Stock? 3 Reasons to Think "Yes"

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock

3 Reasons Why Growth Investors Shouldn't Overlook Fortuna (FSM)
3 Reasons Why Growth Investors Shouldn't Overlook Fortuna (FSM)

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a growth

Landmark Bancorp Q3 Earnings Rise Y/Y on Loan Growth, Credit Gains
Landmark Bancorp Q3 Earnings Rise Y/Y on Loan Growth, Credit Gains

Shares of Landmark Bancorp, Inc. LARK have risen 0.9% since reporting third-quarter 2025 earnings. This compares to the S&P 500 index’s 0.01% growth over the same period. However, over the past

Sterling Stock Before Q3 Earnings: Buy Now or Wait for Results?
Sterling Stock Before Q3 Earnings: Buy Now or Wait for Results?

Sterling Infrastructure, Inc. STRL is scheduled to report third-quarter 2025 results on Nov. 3, after the closing bell.In the last reported quarter, Sterling delivered adjusted earnings per share of

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks: https://www.marketbeat.com/logos/articles/med_20251029154055_royalty-pharma-a-smarter-way-to-profit-from-blockb.jpg
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks

Investing in biotechnology often feels like navigating a minefield. A single failed clinical trial can decimate a stock, while a blockbuster approval can generate spectacular returns. For many